The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Banner BG

KEAP1 Signaling

See how Bayer is investigating KEAP1 signaling across the oncology pipeline

Explore the investigational compounds, tumor types, and clinical trials associated with this area of research.

KEAP1 Signaling

  • Kelch-like ECH-associated protein 1 (KEAP1) functions as an E3 ligase responsible for stabilizing nuclear factor erythroid 2–related factor 2 (NRF2), a transcription factor1

  • The NRF2/KEAP1 pathway is a master regulator of the cellular antioxidant response signaling that plays a crucial role in metabolic reprogramming2

    • Specifically, NRF2 has important roles in regulating inflammatory responses by interfering with pro-inflammatory signaling and decreasing cytokine production3

  • Bayer is currently evaluating the activation of KEAP1 to induce an anti-tumor response in solid tumors4

Tumor Types

Head and neck cancer
Lung cancer
Solid tumors

Related Compound

KEAP1-NRF2 inhibitor (BAY 3605349)

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.